Viridian Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Viridian Therapeutics, Inc. on April 23, 2021. The report details the entry into a material definitive agreement regarding the potential sale of the company's common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to raise up to $50,000,000 through an "at the market" offering program.
Material Changes and Agreements
- Open Market Sale Agreement: On April 23, 2021, the Company entered into an agreement with Jefferies LLC to sell shares of common stock with an aggregate offering price of up to $50,000,000.
- Sale Mechanism: Shares will be sold at prevailing market prices through Jefferies LLC as the agent.
- Compensation: Jefferies LLC will receive a commission of 3.0% of the gross proceeds from any shares sold.
- Obligations: Neither the Company nor the Agent is obligated to sell or buy any shares under this agreement.
- Registration: The offering is conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-237413), effective April 14, 2020.
Outlook, Risks, and Contingencies
The filing explicitly states that no assurance can be given that the Company will sell any shares, nor can the price, amount, or timing of such sales be determined. The Company has agreed to indemnify the Agent against certain liabilities under the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the current share price and market conditions to assess the potential dilution impact of a $50 million offering.
- Confirm the total number of authorized shares available for sale under the existing Form S-3 shelf registration.
- Review the Company's most recent 10-K or 10-Q filings for actual cash position and burn rate to understand the necessity of this capital raise.
- Monitor future filings for actual sales executed under this agreement and the resulting proceeds.